StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)

Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –

Halozyme Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Halozyme Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $611.93M, down 11.7% year over year. For fiscal 2025 it was $480.40M, down 14.5% from the year before. The highest annual figure on record is $561.74M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$480.40M-14.5%
FY2024Dec 31, 2024$561.74M+61.1%
FY2023Dec 31, 2023$348.66M+27.2%
FY2022Dec 31, 2022$274.02M-1.7%
FY2021Dec 31, 2021$278.90M+89.0%
FY2020Dec 31, 2020$147.54M–
FY2019Dec 31, 2019-$63.54M–
FY2018Dec 31, 2018-$66.94M-180.5%
FY2017Dec 31, 2017$83.16M–
FY2016Dec 31, 2016-$80.80M–
FY2015Dec 31, 2015-$25.78M–
FY2014Dec 31, 2014-$61.27M–
FY2013Dec 31, 2013-$79.21M–
FY2012Dec 31, 2012-$52.55M–
FY2011Dec 31, 2011-$18.74M–
FY2010Dec 31, 2010-$52.75M–
FY2009Dec 31, 2009-$57.01M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$292.15M+42.4%
Q1 FY2026Mar 31, 2026$188.74M+30.9%
Q4 FY2025Dec 31, 2025-$89.59M-150.3%
Q3 FY2025Sep 30, 2025$220.62M+33.1%
Q2 FY2025Jun 30, 2025$205.14M+71.2%
Q1 FY2025Mar 31, 2025$144.22M+47.2%
Q4 FY2024Dec 31, 2024$178.15M+71.4%
Q3 FY2024Sep 30, 2024$165.80M+82.2%
Q2 FY2024Jun 30, 2024$119.84M+23.2%
Q1 FY2024Mar 31, 2024$97.99M+73.7%
Q4 FY2023Dec 31, 2023$103.97M+34.9%
Q3 FY2023Sep 30, 2023$90.98M+6.7%
Q2 FY2023Jun 30, 2023$97.26M+176.6%
Q1 FY2023Mar 31, 2023$56.42M-26.2%
Q4 FY2022Dec 31, 2022$77.07M+34.5%
Q3 FY2022Sep 30, 2022$85.29M+11.8%
Q2 FY2022Jun 30, 2022$35.16M-62.5%
Q1 FY2022Mar 31, 2022$76.45M+48.5%
Q4 FY2021Dec 31, 2021$57.31M-26.9%
Q3 FY2021Sep 30, 2021$76.29M+85.6%
Q2 FY2021Jun 30, 2021$93.85M+209.2%
Q1 FY2021Mar 31, 2021$51.47M–
Q4 FY2020Dec 31, 2020$78.42M–
Q3 FY2020Sep 30, 2020$41.10M–
Q2 FY2020Jun 30, 2020$30.36M–
Q1 FY2020Mar 31, 2020-$2.37M-159.8%
Q4 FY2019Dec 31, 2019-$31.02M-6076.9%
Q3 FY2019Sep 30, 2019-$23.54M–
Q2 FY2019Jun 30, 2019-$12.98M–
Q1 FY2019Mar 31, 2019$3.96M–
Q4 FY2018Dec 31, 2018$519.00K-99.6%
Q3 FY2018Sep 30, 2018-$24.87M-390.0%
Q2 FY2018Jun 30, 2018-$19.47M–
Q1 FY2018Mar 31, 2018-$23.15M–
Q4 FY2017Dec 31, 2017$126.42M–
Q3 FY2017Sep 30, 2017$8.58M–
Q2 FY2017Jun 30, 2017-$24.88M–
Q1 FY2017Mar 31, 2017-$26.92M–
Q4 FY2016Dec 31, 2016-$21.93M–
Q3 FY2016Sep 30, 2016-$22.04M–

More Halozyme Therapeutics figures

See a number that looks wrong?